Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending May 3, 2020 Adding a blood test to standard screening may improve early cancer detection, Case series suggests biologics, JAK inhibitors safe during pandemic, Antitumor treatment may increase risk of severe events in COVID-19 patients, IDSA guidelines cover N95 use and reuse, EMBRACA shows no overall survival benefit with talazoparib, More must reads Must reads for theWeek ending April 26, 2020 ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients, Proximal fractures linked to higher mortality, More must readsMust reads for theWeek ending April 19, 2020 N.Y. universal testing: Many COVID-19+ pregnant women are asymptomatic, Update confirms survival benefit with trastuzumab in uterine serous carcinoma, Bone density slow to rebound after lactation in women with HIV, Severe COVID-19 may lower hemoglobin levels, Survey reveals gender pay discrepancies among gyn-oncs, More must readsMust reads for theWeek ending April 5, 2020 High and low trauma yield similar future osteoporotic fracture risk, Water-only fasting may reduce chemo modifications, hospital admissions, Promising efficacy with adavosertib in uterine serous carcinoma, Younger gynecologic cancer patients at risk for early bone loss, PFAS exposure in pregnancy tied to obesity risk in granddaughters, More must readsMust reads for theWeek ending March 29, 2020 Vaginal artesunate quells CIN 2/3 lesions, clears HPV , Reports suggest possible in utero transmission of novel coronavirus 2019, Study challenges role of birth canal exposure in newborn microbiome establishment, CLEOPATRA: Pertuzumab has long-term benefit in HER2+ breast cancer, HCV screening risk factors in pregnant women need updating, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 last »
